Astellas Pharma (MEX:4503N) Inventories, Raw Materials & Components: MXN0 Mil (As of Mar. 2026)


MEX:4503N Astellas Pharma Inc MEX:4503N
78 GF Score
Price MXN253.57
GF Value MXN246.87
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is Astellas Pharma Inventories, Raw Materials & Components?

Astellas Pharma MEX:4503N 78 Inventories, Raw Materials & Components is MXN0 Mil as of Mar. 2026. GuruFocus rates MEX:4503N with a GF Score™ of 78/100 and a GF Value™ of MXN246.87 (Fairly Valued). The stock has 4 warning signs investors should review.

Astellas Pharma's inventories, raw materials & components for the quarter that ended in Mar. 2026 was MXN0 Mil.

Astellas Pharma Inventories, Raw Materials & Components Historical Data

* Premium members only.

The historical data trend for Astellas Pharma's Inventories, Raw Materials & Components can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Astellas Pharma Inventories, Raw Materials & Components Chart

Astellas Pharma Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Inventories, Raw Materials & Components
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Astellas Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Inventories, Raw Materials & Components Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
MEX:4503N
78GF Score
Astellas Pharma Inc MEX:4503N
Inventories, Raw Materials & Components is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Astellas Pharma Inventories, Raw Materials & Components Calculation

Materials and components scheduled for use in making a product.

What does a Inventories, Raw Materials & Components of MXN0 Mil mean?
Astellas Pharma (MEX:4503N) has a Inventories, Raw Materials & Components of MXN0 Mil as of Mar. 2026. Raw materials are the components a company uses for its main products. View historical data on Astellas Pharma and its competitors.
Is Astellas Pharma's Inventories, Raw Materials & Components too high?
Astellas Pharma's current Inventories, Raw Materials & Components is MXN0 Mil. Overall, Astellas Pharma has a GF Score™ of 78/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Astellas Pharma's Inventories, Raw Materials & Components compare to LLY and JNJ?
Astellas Pharma's Inventories, Raw Materials & Components of MXN0 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Inventories, Raw Materials & Components for a Drug Manufacturers company?
A good Inventories, Raw Materials & Components depends on the Drug Manufacturers industry context. However, Inventories, Raw Materials & Components should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Inventories, Raw Materials & Components mean?
A high Inventories, Raw Materials & Components can signal that a stock is expensive relative to its fundamentals. Raw materials are the components a company uses for its main products. View historical data on Astellas Pharma and its competitors. Astellas Pharma's current Inventories, Raw Materials & Components is MXN0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Astellas Pharma stock overvalued right now?
Based on GuruFocus' analysis, Astellas Pharma (MEX:4503N) is currently considered Fairly Valued. The stock's GF Value™ is MXN246.87, compared to a current price of MXN253.57 — trading 2.7% above its estimated fair value. The current Inventories, Raw Materials & Components is MXN0 Mil. Astellas Pharma's overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Inventories, Raw Materials & Components calculated?
Inventories, Raw Materials & Components is calculated from a company's financial statements. For Astellas Pharma (MEX:4503N), the current Inventories, Raw Materials & Components is MXN0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Astellas Pharma (MEX:4503N) Overvalued in 2026?

Based on GuruFocus' analysis, Astellas Pharma stock appears to be overvalued. The current stock price of MXN253.57 is trading 2.7% above its estimated GF Value™ of MXN246.87. GuruFocus considers Astellas Pharma to be Fairly Valued.

Key valuation signals for MEX:4503N:

  • Inventories, Raw Materials & Components: MXN0 Mil
  • GF Value™: MXN246.87 vs. price of MXN253.57 (2.7% above fair value)
  • GF Score™: 78/100 with 4 warning signs

No single metric tells the full story. See the MEX:4503N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Astellas Pharma Business Description

Address 2-5-1 Nihonbashi-Honcho, Chuo-ku, Tokyo, JPN, 103-8411
Astellas Pharma Inc is a specialty international pharmaceutical company. The company focuses on accelerating the discovery, development, and commercialization of ground-breaking innovations that could redefine expectations of care for difficult-to-treat diseases. The group is committed to driving innovation in immuno-oncology, gene therapy, mitochondria, blindness and regeneration, and targeted protein degradation. Its core products include anticancer agents like XTANDI, XOSPATA, and PADCEV; VEOZAH for the treatment of vasomotor symptoms due to menopause; Betanis / Myrbetriq / BETMIGA for the treatment of overactive bladder (OAB); and Prograf, an immunosuppressant for organ transplantation.
78GF Score

Get the complete analysis for MEX:4503N

Inventories, Raw Materials & Components is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN253.57
Price
MXN246.87
GF Value